Enoxaparin Use in Hospitalized SARS-CoV-2-Positive Patients with Elevated D-Dimer: A Pilot Study

1. Chen, N, Zhou, M, Dong, X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. The Lancet. 2020;395:507-513.
Google Scholar | Crossref | Medline2. Li, Taisheng, Lu, H, Zhang, W. Clinical observation and management of COVID-19 patients. Emerg Microb Infect. 2020;9(1):687-690.
Google Scholar | Crossref | Medline3. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506.
Google Scholar | Crossref | Medline4. Lin, L, Lu, L, Cao, W, Li, T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg. microbes & infect. 2020;9(1):727-732.
Google Scholar | Crossref | Medline5. The RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020;384(8):693-704.
Google Scholar | Crossref | Medline6. Hossri, S, Shadi, M, Hamarsha, Z, et al. Clinically significant anticardiolipin antibodies associated with COVID-19. J Crit Care. 2020;59:32-34.
Google Scholar | Crossref | Medline7. Yuriditsky, E, Horowitz, Merchan, C, et al. Thromboelastography profiles of critically ill patients with coronavirus disease 2019. Crit Care Med. 2020;48(9):1319-1326.
Google Scholar | Crossref | Medline8. Klok, FA, Kruip, MJHA, Meer Van der, NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
Google Scholar | Crossref | Medline9. COVID-19 Treatment Guidelines Panel . Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Bethesda,MD: National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/. Accessed August 31, 2020.
Google Scholar10. Paranjpe, I, Fuster, V, Lala, A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122-124.
Google Scholar | Crossref | Medline11. Barnes, GD, Burnett, A, Allen, A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: Interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50:72-81.
Google Scholar | Crossref | Medline12. Schulman, S, Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
Google Scholar | Crossref | Medline | ISI13. Cohen, AT, Davidson, BL, Gallus, AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ. 2006;332(7537):325-329.
Google Scholar | Crossref | Medline14. Leizorovicz, A, Cohen, AT, Turpie, AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879.
Google Scholar | Crossref | Medline | ISI15. Kabrhel, C, Mark Courtney, D, Camargo, CA, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med. 2010;17(6):589-597.
Google Scholar | Crossref | Medline | ISI16. Songping, C, Shuo, C, Xiunan, L. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
Google Scholar | Crossref | Medline17. Artifoni, M, Danic, G, Gautier, G, et al. Systemic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1): 211-216.
Google Scholar | Crossref | Medline18. Yao, Y, Cao, J, Wang, Q, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8:49.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif